What Will Amyris Gain and Sacrifice to Court Tire Manufacturers for Expansion?

The tire market presents a giant opportunity for Amyris going forward, but the gains are accompanied by sacrifices, too.

May 1, 2014 at 2:00PM

G

A worker stands next to 200,000 liter fermenters at a biorefinery in Brotas, Brazil. Source: Amyris

I recently introduced the opportunity presented by the tire industry for the synthetic biology platform under development by Amyris (NASDAQ:AMRS) and partner Kuraray. This year three major tire manufacturers are expected to complete road tests with low-rolling resistance tires created with Liquid Farnesene Rubber, which is significantly easier to work with during manufacturing than the component it replaces. In all, 13 of the world's top tire manufacturers are working with the company on development and commercialization. If new formulations can improve upon current-generation tires aimed at improving fuel economy, such as Assurance Fuel Max from The Goodyear Tire & Rubber Company (NASDAQ:GT), then drivers could save over 2,600 miles of fuel over the lifetime of their vehicles' tires.

The opportunity could be huge. In fact, CEO John Melo believes tire manufactures could fund the completion of a half-completed 65,000 metric-ton-per-year farnesene facility in Brazil by 2016 that would be fully dedicated to the tire industry. While Amyris is guiding to be cash flow positive in 2014 and profitable in 2015, such a move would greatly aid the cash-strapped company and add to its growing momentum. What does Amyris have to gain from the tire industry? And more importantly for investors, what does it have to give up to capture the opportunity?

The opportunity
How does the manufacturing process work? Liquid Farnesene Rubber is created when polymerized farnesene acts as a binding agent to strengthen the adhesion of rubber and fillers. In addition to reducing viscosity during manufacturing, Liquid Farnesene Rubber improves tire shape, stability, and performance, which also results in improved fuel efficiency. Judging from the composition of a standard tire, it could become an important part of the manufacturing process.

G

Source: Amyris

The global tire market has an estimated value of $140 billion per year. Despite supporting over two dozen players from around the world, the top four manufacturers account for the majority of sales. That shouldn't limit the opportunity for Amyris, however, which will begin to sell farnesene to Kuraray for processing and distribution to tire manufacturers sometime in 2014. The farnesene initially produced will come from the company's biorefinery in Brotas, Brazil, although the goal is for a larger facility to begin producing the molecule exclusively for the tire market in 2016. A 65,000 MT facility dedicated to farnesene production for the tire market could generate $320 million in annual sales if product was sold for a conservative average selling price of $4 per liter.

Want to see how Amyris' polymerized farnesene fits into the tire manufacturing process? Watch this five-minute video that demonstrates how tires are made from start to finish.

In addition to farnesene, Amyris is working with Michelin to develop a process for producing commercial quantities of the molecule isoprene, or natural rubber. While the development is neither directly related to nor dependent on the commercialization of Liquid Farnesene Rubber, Amyris could leverage its existing relationships with tire manufacturers to sell product -- significantly reducing time spent on courting partners and navigating the market.

The sacrifice
Tire manufacturers may be willing to fund the completion of the half-completed facility by 2016, but they won't be doing so for free. The details of such a proposal are unclear now, although investors should probably expect Amyris to sacrifice quite a bit in the short term to reap the long-term benefits of such a facility. The company's bargaining power is limited due to its less than envious cash reserves, which means it will need to rely heavily on the tire manufacturer or manufacturers for completing the facility or raise dilutive funds to match a portion of the capital expenditures. That former may result in less favorable profit-sharing terms for production (up to a certain volume or volumes). In other words, Amyris would capture less than a 50% portion of sales and profits for the first X metric tons of production.

That's all just speculation at this point. Remember, sugarcane supplier Usina Sao Martinho -- the other half of the SMA Indústria Química joint venture with Amyris -- has a stake in the 65,000 MT facility, too. Exactly how a third group (the tire manufacturers) would fit into the ownership structure of the manufacturing facility is difficult to predict. But it doesn't take much to see that Amyris will have to make sacrifices to complete the halted construction.

Foolish bottom line
Let's face it: An investment in Amyris comes with unique risks. Future expansion has the potential to result in share dilution or fairly restricted profit-sharing contracts. That will cap shareholder gains and/or revenue potential. But I think many often characterize the company based on impressions formed during the struggles faced in 2012 and 2013. The company has revamped its commercialization approach by focusing on engineering principles when scaling biology, which has resulted in lower production costs and more reliable operations. Given the value that is being created by Amyris' platform and the future potential that could be enabled, I would suggest that investors give a deeper look before blindly dismissing the opportunity.

Invest in tires for incredible growth, or something more?
Amyris has the potential to enable massive returns for long term investors, but investors will have to be patient and deal with setbacks, which are inevitable in the industry. Would David Gardner, who recently grabbed his first 100-bagger, invest in the developmental company? How does he choose stocks anyway? You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Maxx Chatsko owns shares of Amyris. Check out his personal portfolioCAPS pageprevious writing for The Motley Fool, or his work for SynBioBeta to keep up with developments in the synthetic biology industry.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers